Germanymerck-animal-health.com
Merck & Co., Inc. (branded as MSD outside the United States and Canada) is a global biopharmaceutical company engaged in the discovery, development, manufacturing, and commercialization of human prescription medicines, vaccines, and biologic therapies. The company’s portfolio and pipeline span major therapeutic areas including oncology, infectious diseases, vaccines, cardiometabolic conditions, and immunology.
Merck also operates a substantial animal health business (Merck Animal Health/MSD Animal Health), providing veterinary pharmaceuticals, vaccines, and health management solutions for companion and production animals. The company maintains a worldwide network of research, clinical development, and manufacturing sites supporting small-molecule, biologics, and vaccine production.
Note: Merck & Co., Inc. (MSD) is distinct from Merck KGaA, Darmstadt, Germany, which operates separately and uses different branding in North America.
Also known as MSD, Merck Sharp & Dohme, MSD Animal Health, Merck & Co., Inc., Merck Animal Health, Merck Sharp & Dohme Corp., and Merck Research Laboratories.
chemXplore tracks 9 projects involving Merck, of which 3 are active.
Merck's role on them: Owner, Investor / Financier, Operator, and Developer.
2 new construction and 1 expansion.
Contractors are recorded on 1 of these 3 projects For subscribers
Phase 2b trial met HiSCR50 at week 16 for two dosing regimens; HiSCR75 and DLQI showed numeric gains; safety comparable to placebo; results to inform Phase 3.
Exclusive global licence for a preclinical oral KRAS G12D (ON) molecular‑glue inhibitor; $400M upfront and $2.13B total potential; Merck to lead development and commercialization.
BLA for I‑DXd seeking accelerated approval in extensive‑stage SCLC withdrawn after FDA said Phase 2 data were insufficient; Phase 3 programmes continue.
Tri-specific Wnt-pathway agonist showed non-inferior BCVA gains vs ranibizumab at week 52; higher rates of PDR, vitreous hemorrhage and discontinuations observed.
FDA updates PAH therapy label to include HYPERION data showing a 76% reduction in clinical worsening when added to background therapy for patients diagnosed within 12 months.
First subcutaneous immune‑checkpoint inhibitor in Japan; can be given in as little as one minute and showed comparable exposure and response to IV pembrolizumab in a phase‑3 trial.
CHMP recommends approval after KEYNOTE-B15 showed event-free survival, overall survival and pathologic complete response gains; European Commission decision expected Q4 2026.
First Phase 3 success for an individualized mRNA neoantigen therapy; trial met RFS and DMFS in completely resected stage IIB–IV melanoma; OS pending; safety consistent.
By country, the most active first. active / all projects
